Novan Investor Relations Material
Latest events
Q1 2023
Novan
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Novan Inc
Access all reports
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. It is engaged in developing nitric oxide-based therapeutics for the treatment of skin pathologies, including acne vulgaris and other inflammatory conditions such as psoriasis, atopic dermatitis, wound healing, endometriosis, hidradenitis suppurativa (HS) and eczema; and microbial infections in dermatology such as MRSA infections. The company's product candidate pipeline consists of two Phase 3 clinical stage candidates: M834 for HS and an acne treatment; as well as a Phase 2 clinical candidate for topical fungal infections.
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
NOVN
Country
πΊπΈ United States